期刊文献+

阿加曲班杂质的合成 被引量:2

Synthesis of Impurity in Argatroban
下载PDF
导出
摘要 为有效控制阿加曲班原料药质量并建立质量标准,以4-碘苯胺为起始原料,经与甲基丙烯醛环合、与苄硫醇偶联、氧化、水解制备阿加曲班杂质3-甲基喹啉-6-磺酸,并优化了合成工艺。优化条件下,杂质纯度99.1%(HPLC),总收率49.5%,其结构经^(1)H NMR、^(13)C NMR和HRMS表征确证。合成工艺原料易得,反应条件温和,制备的杂质纯度高,可作为阿加曲班药物质量控制的杂质对照品。 In order to effectively control the quality of Argatroban and establish the quality standard,4-iodoaniline was used as the starting material,and the intermediate was obtained by cyclization with methacrolein.Argatroban impurity 3-methylquinoline-6-sulfonic acid was synthesized from the intermediate via cross-coupling with benzyl mercaptan,oxidation,hydrolysis,and purification with a purity of 99.1%(HPLC)and an overall yield about 49.5%.The conditions for the synthetic process were optimized.Their structures were confirmed by^(1)H NMR,^(13)C NMR and HRMS.This synthetic process is reasonable and feasible,the reaction conditions are mild,and the purity of the impurity is high.It can be used as the impurity reference substance for the quality control of Argatroban.
作者 胡中元 唐旭静 邢磊 张晓玲 刘彦龙 HU Zhong-yuan;TANG Xu-jing;XING Lei;ZHANG Xiao-ling;LIU Yan-long(Research Institute of Chia Tai Tianqing Pharmaceutical Group Co.,Ltd.,Nanjing 210000,China)
出处 《精细化工中间体》 CAS 2023年第3期38-40,共3页 Fine Chemical Intermediates
关键词 阿加曲班 4-碘苯胺 杂质 Argatroban 4-iodoaniline impurity
  • 相关文献

参考文献4

二级参考文献25

  • 1袁莉娟,刘爱民,刘蕾.新型凝血酶抑制剂阿加曲班[J].中国新药杂志,2005,14(2):230-234. 被引量:34
  • 2Daneschvar HL,Daw H.Heparin-induced thrombocytopenia(an overview).Int J Clin Pract,2007;61:130-137 被引量:1
  • 3Lunven C,Gauffeny C,Lecoffre C,et al.Inhibition by Argatroban,a specific thrombin inhibitor,of platelet activation by fibrin clot-associated thrombin.Thromb Haemost.1996;75:154-160 被引量:1
  • 4Berry CN,Girardot C,Lecoffre C,at al.Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporatad thrombin:comparison with heparin and recombinant Hirudin.Thromb Haemost,1994;72:381-386 被引量:1
  • 5Jang IK,Cold HK,Ziskind AA,et al.Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.Circulation,1990;81:219-225 被引量:1
  • 6Sinnsove PR,Simes J,Yusuf S,et al.Direct thrombin iahibiton in acute coronary syndromes:effectin patients undergoing early percutaneous coronary intervention.Eur Heart J JT-European heart journal,2005;26:2396-2403 被引量:1
  • 7Cruz-Conzalez I,Sanchez-Ledesma M,Baron SJ,et al.Efficacy and safety of argatroban with or without glycoprotein Ⅱb/Ⅲa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome.J Thumb Thrombolysis JY-Journal of thrombosis and thrombolysis,2008;25:214-218 被引量:1
  • 8Matthai WH Jr,Hursting MJ,Lewis BE,et al.Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia.Thromb Res,2005;116:121-126 被引量:1
  • 9Lewis BE.Walenga JM.Argatroban in HIT type Ⅱ and acutecoronary syndrome.Pathophysiol Haemost Thromb.2002;32 Suppl 3:46-55 被引量:1
  • 10Jeanne M. Rhea,Marion L. Snyder,Anne M. Winkler,Charbel Abou-Diwan,Corinne R. Fantz,James C. Ritchie,Fania Szlam,Kenichi A. Tanaka,Ross J. Molinaro.Development of a fast and simple liquid chromatography–tandem mass spectrometry method for the quantitation of argatroban in patient plasma samples[J].Journal of Chromatography B.2012 被引量:1

共引文献16

同被引文献7

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部